Applied DNA Sciences Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Applied DNA Sciences Inc Company

Applied DNA Sciences, Inc. is a biotechnology company. The Company is engaged in developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Company operates through three segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. Therapeutic DNA Production Services segment operations consist of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of messenger RNA (mRNA) therapeutics. MDx Testing Service segment operations consist of performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. DNA Tagging and Security Products and Services segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services.

Applied DNA Sciences Inc Info



Ticker SymbolAPDN

Company nameApplied DNA Sciences Inc

IPO dateAug 24, 2001

CEOMs. Judith Murrah

Number of employees46

Security typeOrdinary Share

Fiscal year-endAug 24

Address50 Health Sciences Drive

CitySTONY BROOK

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code11790

Phone16312408800

Websitehttps://adnas.com/

Ticker SymbolAPDN

IPO dateAug 24, 2001

CEOMs. Judith Murrah

Company Executives of Applied DNA Sciences Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Clay Shorrock, J.D.

Chief Executive Officer

18.70K

+467275.00%

Ms. Beth M. Jantzen

Chief Financial Officer

18.69K

+623033.33%

Mr. Robert B. (Bob) Catell

Independent Director

1.00

--

Mr. Joseph D. Ceccoli

Independent Director

1.00

--

Ms. Judith Murrah

Chairman of the Board

1.00

-66.67%

Dr. Yacov A. Shamash, Ph.D.

Independent Director

1.00

--

Ms. Elizabeth M. Schmalz Shaheen

Independent Director

--

Mr. Sanjay M. Hurry

Executive Director - Investor Relations and Corporate Communications

--

Name

Name/Position

Position

Shareholding

Change

Mr. Clay Shorrock, J.D.

Chief Executive Officer

18.70K

+467275.00%

Ms. Beth M. Jantzen

Chief Financial Officer

18.69K

+623033.33%

Mr. Robert B. (Bob) Catell

Independent Director

1.00

--

Mr. Joseph D. Ceccoli

Independent Director

1.00

--

Ms. Judith Murrah

Chairman of the Board

1.00

-66.67%

Dr. Yacov A. Shamash, Ph.D.

Independent Director

1.00

--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Product and authentication services - Large scale DNA production

161.00K

52.89%

Product and authentication services - Supply chain

91.32K

30.00%

Research and development services

52.07K

17.11%

No Data

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Product and authentication services - Large scale DNA production

161.00K

52.89%

Product and authentication services - Supply chain

91.32K

30.00%

Research and development services

52.07K

17.11%

Shareholding Stats

Updated: Mon, Nov 3

Shareholders

Shareholder Types

Shareholders

Proportion

Anson Funds Management LP.

0.79%

Sabby Management, LLC

0.41%

Jantzen (Beth M)

0.32%

Shorrock (Clay)

0.32%

UBS Financial Services, Inc.

0.19%

Other

97.98%

Shareholders

Proportion

Anson Funds Management LP.

0.79%

Sabby Management, LLC

0.41%

Jantzen (Beth M)

0.32%

Shorrock (Clay)

0.32%

UBS Financial Services, Inc.

0.19%

Other

97.98%

Shareholder Types

Shareholders

Proportion

Hedge Fund

0.79%

Individual Investor

0.63%

Investment Advisor/Hedge Fund

0.41%

Investment Advisor

0.19%

Corporation

0.16%

Other

97.82%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

59

89.41K

1.51%

+65.56K

2025Q2

62

34.98K

6.73%

-8.84K

2025Q1

84

45.20K

34.86%

+11.50K

2024Q4

79

25.60M

46.39%

+1.44M

2024Q3

74

1.08M

9.78%

+703.30K

2024Q2

73

1.19M

10.83%

+424.27K

2024Q1

67

243.32K

209.10%

+86.27K

2023Q4

64

96.98K

13.46%

-84.74K

2023Q3

66

149.12K

21.28%

-82.31K

2023Q2

68

142.47K

21.43%

-74.27K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Anson Funds Management LP.

46.51K

3.6%

+41.94K

+918.33%

Jun 30, 2025

Sabby Management, LLC

24.36K

1.89%

+17.39K

+249.63%

Jun 30, 2025

Jantzen (Beth M)

3.00

0%

--

Apr 03, 2025

Shorrock (Clay)

4.00

0%

--

Apr 03, 2025

UBS Financial Services, Inc.

11.13K

0.86%

+8.82K

+381.65%

Jun 30, 2025

UBS Switzerland AG

493.00

0.04%

+493.00

--

Jun 30, 2025

Tower Research Capital LLC

222.00

0.02%

+190.00

+593.75%

Jun 30, 2025

SBI Securities Co., Ltd.

146.00

0.01%

+79.00

+117.91%

Jun 30, 2025

Grossman (Bruce)

111.00

0.01%

+111.00

--

Feb 02, 2024

Sanctuary Advisors, LLC

20.00

0%

+20.00

--

Dec 31, 2024

Related ETFs



Name

Proportion

No Data

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Mar 12, 2025

Merger

50→1

Mar 12, 2025

Merger

50→1

Mar 12, 2025

Merger

50→1

Mar 12, 2025

Merger

50→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Date

Type

Ratio

Mar 12, 2025

Merger

50→1

Mar 12, 2025

Merger

50→1

Mar 12, 2025

Merger

50→1

Mar 12, 2025

Merger

50→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1